<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tardive dyskinesia: Prevention, treatment, and prognosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tardive dyskinesia: Prevention, treatment, and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tardive dyskinesia: Prevention, treatment, and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tsao-Wei Liang, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Howard I Hurtig, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen Marder, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tardive dyskinesia (TD) is a medication-induced hyperkinetic movement disorder associated with the use of dopamine receptor-blocking agents, including first- and second-generation antipsychotic drugs, <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a>, and <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">prochlorperazine</a>.</p><p>The most common manifestations of TD involve spontaneous movements of the mouth and tongue, but the arms, legs, trunk, and respiratory muscles can also be affected. Less commonly, the prominent feature is dystonia involving a focal area of the body such as the neck. TD can be irreversible and lifelong, with major negative impacts on psychologic health and quality of life.</p><p>TD is important to recognize, since early discontinuation of the offending drug offers the best chance of recovery. However, in patients who require ongoing antipsychotic drug therapy for management of psychiatric disorders, symptomatic therapies for TD can help lessen movements, if only partially.</p><p>This topic will review the prevention and management of TD. Other aspects of TD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4909.html" rel="external">"Tardive dyskinesia: Etiology, risk factors, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Prevention and early detection of TD are of paramount importance. The only certain method to prevent TD is to remain vigilant when treating with dopamine receptor-blocking agents.</p><p class="headingAnchor" id="H3"><span class="h2">Safe prescribing practices</span><span class="headingEndMark"> — </span>When a dopamine receptor-blocking agent is deemed necessary, prevention of TD begins at the time of prescription. Guidelines for prescribing drugs to help decrease the risk of TD include the following [<a href="#rid1">1-3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Use dopamine receptor-blocking agents only when there is a clear indication for their clinical use and safer effective alternatives are lacking.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For antipsychotic drugs, continuous treatment beyond three to six months should only be considered when the need for continuous treatment and potential harms of nontreatment are deemed to be greater than the risks of TD and other potential toxicities (mainly chronic psychotic illness).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a>, continuous use for longer than 12 weeks should be avoided. The association between metoclopramide and TD is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4909.html" rel="external">"Tardive dyskinesia: Etiology, risk factors, clinical features, and diagnosis", section on 'Metoclopramide'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prescribe the lowest effective dose of these agents for the shortest duration necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Consider choosing second-generation antipsychotics over first-generation antipsychotics to lessen the risk of TD, especially in older patients, while acknowledging that second-generation antipsychotics still carry risk. (See  <a class="medical medical_review" href="/z/d/html/4909.html" rel="external">"Tardive dyskinesia: Etiology, risk factors, clinical features, and diagnosis", section on 'Antipsychotic drugs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitor for acute drug-induced parkinsonism and akathisia, which serve as risk factors and potential warning signs for TD. Drug-induced parkinsonism may also mask signs of TD. Use the lowest effective dose when treating with dopamine receptor blockers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use particular care in older adults (50 years and older), patients with affective disorder, patients with treatment-resistant schizophrenia, and females, as these groups are at an increased risk for TD  (<a class="graphic graphic_table graphicRef118233" href="/z/d/graphic/118233.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoid chronic use of prophylactic anticholinergic drugs whenever possible, since they do not prevent TD and may mask or even aggravate extrapyramidal symptoms when they arise.</p><p></p><p class="headingAnchor" id="H3559111162"><span class="h2">Informed consent and education</span><span class="headingEndMark"> — </span>As an iatrogenic disorder, TD has medicolegal implications [<a href="#rid4">4</a>]. Thus, it is important to inform patients of the risk of developing TD before treating with antipsychotic drugs, certain antiemetics, and <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a>, to discuss treatment goals and alternatives, and to document discussion in the medical record.</p><p>Although there is no consensus, some experts also advocate obtaining written informed consent from patients with decision-making capacity or from family members of patients who are unable to consent.</p><p>Informed consent provides an opportunity to educate the patient and family members or caregivers, so that they recognize abnormal movements should they occur.</p><p class="headingAnchor" id="H326177066"><span class="h2">Monitoring during treatment</span><span class="headingEndMark"> — </span>All patients receiving long-term antipsychotic drugs or <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> should be regularly screened for signs of TD.</p><p>Screening for TD consists of physical examination, evaluating for abnormal involuntary movements of the face, mouth, jaw, or extremities. The tongue should be observed with the mouth held open. While standing or walking, the patient is observed for abnormal movements of the trunk or limbs.</p><p>Clinicians may choose to use the Abnormal Involuntary Movement Scale (AIMS) for documenting the examination  (<a class="graphic graphic_form graphicRef51103" href="/z/d/graphic/51103.html" rel="external">form 1</a>). The AIMS is a 14-item scale that includes examination of the head, dentition, neck, limb, and truncal movements and rating of severity between 0 (normal-absent) and 4 (severe).</p><p class="headingAnchor" id="H5"><span class="h1">INITIAL MANAGEMENT</span><span class="headingEndMark"> — </span>Current therapies for TD relieve symptoms but do not treat the underlying dopaminergic blockade. Thus, early detection of the offending agent is crucial.</p><p class="headingAnchor" id="H6"><span class="h2">Discontinue offending agent, if possible</span><span class="headingEndMark"> — </span>The offending drug should be discontinued when TD first emerges, if possible  (<a class="graphic graphic_algorithm graphicRef131318" href="/z/d/graphic/131318.html" rel="external">algorithm 1</a>). TD is not always permanent, and the earlier the drug is discontinued, the better chance for improvement or resolution of TD. (See <a class="local">'Prognosis'</a> below.)</p><p>Antipsychotic drug cessation (or dose reduction) must be carefully considered in the context of the underlying psychiatric illness and the potential for relapse or worsening of psychotic symptoms. In those with severe psychiatric illness, including schizophrenia, antipsychotic drug cessation is often not possible. (See  <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Antipsychotic therapy'</a>.)</p><p>When tapering a dopamine receptor-blocking agent, clinicians and patients should be aware of the following [<a href="#rid5">5,6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The drug should be withdrawn slowly, over weeks to months depending on the underlying condition and the duration of TD. Abrupt withdrawal may worsen or precipitate TD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TD may take several weeks to improve. In some cases, TD may take months or years to remit or may never completely resolve.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>New-onset or worsened dyskinesia may occur during drug withdrawal (withdrawal-emergent dyskinesia). Such dyskinesias often clear spontaneously over several weeks and do not require specific treatment. In severe cases, the drug may need to be reintroduced and tapered more slowly [<a href="#rid7">7</a>]. Alternatively, concurrent symptomatic therapy for TD may be initiated in an attempt to facilitate the taper. (See <a class="local">'Persistent, moderate to severe TD'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TD may recur if a dopamine receptor-blocking agent is reintroduced. When possible, a second-generation antipsychotic drug with a low risk of TD should be used in preference to high-potency, first-generation drugs in patients with a history of TD who require reintroduction of antipsychotic therapy.</p><p></p><p>Despite the presumption and practice of discontinuing or reducing the dopamine receptor blocker, the effectiveness of this practice has not been well studied prospectively [<a href="#rid8">8-10</a>]. Studies primarily involve patients with chronic psychiatric illness and longstanding TD. A 2018 systematic review identified two trials that evaluated antipsychotic dose reduction versus dose maintenance in a total of 17 patients with TD [<a href="#rid9">9</a>]. Pooled data showed that dose reduction was associated with a trend toward a clinically important reduction in TD severity (relative risk 0.42, 95% CI 0.17-1.04).</p><p class="headingAnchor" id="H7"><span class="h2">Patients who require ongoing antipsychotic therapy</span></p><p class="headingAnchor" id="H708459590"><span class="h3">Patients on a first-generation antipsychotic drug</span><span class="headingEndMark"> — </span>Often when patients with severe psychiatric disease develop TD on a first-generation antipsychotic drug, antipsychotic therapy cannot be safely discontinued. For such patients, we suggest switching to a second-generation antipsychotic drug with lower TD risk, whenever possible [<a href="#rid11">11</a>]. Such a switch may not exacerbate TD and may result in a reduction in TD severity over time, particularly for early and mild symptoms.</p><p>For longstanding TD, clinicians and patients should be aware that improvement in symptoms may take months or years, and in some cases there may be no observable benefit. Therefore, the potential benefits of a switch may not outweigh the risk of worsening psychosis for longstanding TD.</p><p>There are no randomized trials comparing the effects of different second-generation antipsychotic drugs in patients with TD caused by a first-generation antipsychotic drug. Risk of TD varies among second-generation drugs, largely in relation to their potency as dopaminergic D2 receptor blockers. <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">Clozapine</a>, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>, and <a class="drug drug_general" data-topicid="9087" href="/z/d/drug information/9087.html" rel="external">iloperidone</a> have relatively weak affinity for dopamine receptors and thus carry a potentially lower risk of causing or exacerbating TD. (See  <a class="medical medical_review" href="/z/d/html/4909.html" rel="external">"Tardive dyskinesia: Etiology, risk factors, clinical features, and diagnosis", section on 'Antipsychotic drugs'</a>.)</p><p>The low affinity for dopamine receptors makes <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> a preferable second-generation antipsychotic in the setting of TD. The evidence in support of clozapine consists largely of observational studies and secondary analyses of randomized trials [<a href="#rid12">12-18</a>]. However, the rare but potentially serious risk of bone marrow toxicity and the need for monitoring of blood counts make it an impractical choice for most practitioners. Because <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> does not carry this same risk, it is a more practical option and may have similar ameliorating effects on TD [<a href="#rid19">19-21</a>]. Administration of clozapine is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/14772.html" rel="external">"Schizophrenia in adults: Guidelines for prescribing clozapine"</a>.)</p><p>Choosing a second-generation antipsychotic drug such as <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a> and <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> is also an option that may be preferable over continuing the first-generation antipsychotic therapy [<a href="#rid11">11,22-27</a>]. Sixty patients with TD on a first-generation antipsychotic were randomly assigned to either risperidone or olanzapine after a three- to seven-day washout period of the original antipsychotic [<a href="#rid25">25</a>]. At 24 weeks, Abnormal Involuntary Movement Scale (AIMS) scores by blinded raters improved over baseline in both groups (risperidone: -7.4 points, olanzapine: -6.2 points).</p><p>The mechanism of benefit of <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> or other second-generation drugs is likely primarily an antipsychotic drug "sparing" effect, in which gradual improvement of TD occurs with weaker dopamine-blocking effects. A direct antidyskinetic effect is less likely. With high doses of antipsychotic drugs, TD may be masked by parkinsonism, but this practice is not recommended [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H231670415"><span class="h3">Patients on a second-generation antipsychotic drug</span><span class="headingEndMark"> — </span>When patients develop TD on a second-generation antipsychotic drug with no prior exposure to dopamine receptor-blocking agents, the indication and dose of the drug should be reviewed. In some cases, a lower effective dose or an alternative class of drugs may be used.</p><p>If the patient requires ongoing therapy for psychiatric disease and the severity of TD is bothersome, clinicians may consider a switch to <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, based on the data reviewed above. (See <a class="local">'Patients on a first-generation antipsychotic drug'</a> above.)</p><p>Other patients may elect to stay on the same second-generation drug and try a symptomatic therapy such as vesicular monoamine transporter type 2 (VMAT2) inhibitor if movements are bothersome enough to require treatment. (See <a class="local">'Persistent, moderate to severe TD'</a> below.)</p><p class="headingAnchor" id="H34928682"><span class="h2">Assess need for symptomatic therapy</span><span class="headingEndMark"> — </span>Symptoms of TD can be disfiguring and stigmatizing. However, some patients are less troubled or aware of their symptoms and may not require as aggressive an approach. For patients with ongoing symptoms despite an optimized medical regimen, drug treatment for TD should be considered after weighing an individual's level of disability and quality of life with potential side effects and burden of additional treatments.</p><p class="headingAnchor" id="H123969412"><span class="h1">PERSISTENT, MODERATE TO SEVERE TD</span></p><p class="headingAnchor" id="H4058636010"><span class="h2">Overview of approach</span></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with persistent and bothersome TD, vesicular monoamine transporter type 2 (VMAT2) inhibitors are the primary symptomatic therapy  (<a class="graphic graphic_algorithm graphicRef131318" href="/z/d/graphic/131318.html" rel="external">algorithm 1</a>). Benzodiazepine therapy is sometimes helpful for mild symptoms but is unlikely to help more severe TD. (See <a class="local">'Vesicular monoamine transporter type 2 inhibitors'</a> below and <a class="local">'Other drug treatments'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For the subset of patients with tardive dystonia (eg, cervical and truncal dystonia, blepharospasm), botulinum toxin injections are a localized option that may spare the need for systemic drug therapy  (<a class="graphic graphic_algorithm graphicRef131318" href="/z/d/graphic/131318.html" rel="external">algorithm 1</a>). (See <a class="local">'Tardive dystonia'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with refractory TD despite symptomatic therapies should be referred to a movement disorder specialist for consideration of deep brain stimulation (DBS). (See <a class="local">'Deep brain stimulation (DBS)'</a> below.)</p><p></p><p class="headingAnchor" id="H2955045737"><span class="h2">Vesicular monoamine transporter type 2 inhibitors</span><span class="headingEndMark"> — </span>VMAT2 inhibitors are the main symptomatic drug therapy available for TD. In patients with moderate to severe or disabling TD associated with antipsychotic therapy, VMAT2 inhibitors can be associated with meaningful reductions in motor signs and symptoms [<a href="#rid28">28-30</a>].</p><p>They can be used with or without concurrent antipsychotic drug therapy. The drugs act centrally to suppress TD by depleting dopamine storage in presynaptic vesicles.</p><p class="headingAnchor" id="H2139228047"><span class="h3">Selecting an agent</span><span class="headingEndMark"> — </span>There are three available VMAT2 inhibitors for hyperkinetic disorders such as TD. <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">Tetrabenazine</a> has been available for decades and was approved by the US Food and Drug Administration (FDA) in 2008 for chorea in patients with Huntington disease. Two newer VMAT2 inhibitors, <a class="drug drug_general" data-topicid="112668" href="/z/d/drug information/112668.html" rel="external">valbenazine</a> and <a class="drug drug_general" data-topicid="112590" href="/z/d/drug information/112590.html" rel="external">deutetrabenazine</a>, were FDA approved in 2017 for the treatment of TD.</p><p>The three drugs have not been compared directly, and regional availability and cost influence agent selection in some cases. <a class="drug drug_general" data-topicid="112668" href="/z/d/drug information/112668.html" rel="external">Valbenazine</a> and <a class="drug drug_general" data-topicid="112590" href="/z/d/drug information/112590.html" rel="external">deutetrabenazine</a> are not approved in Canada, for example. Assuming availability of all three, we generally prefer the newer agents, based primarily on longer half-life and convenience.</p><p>The quality of the evidence for each of the three drugs is not uniform, but the overall finding of benefit over placebo is consistent. For <a class="drug drug_general" data-topicid="112668" href="/z/d/drug information/112668.html" rel="external">valbenazine</a> and <a class="drug drug_general" data-topicid="112590" href="/z/d/drug information/112590.html" rel="external">deutetrabenazine</a>, the available evidence consists of randomized trials with low risk of bias and good sample sizes [<a href="#rid28">28</a>]. The duration of the randomized phase of the trials was relatively short, and as little as four to six weeks in some studies. Long-term follow-up data are based primarily on open-label extension phases of the randomized trials. Data on <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">tetrabenazine</a> have a higher risk of bias, smaller sample sizes, and inadequate blinding, yielding lower confidence; on the other hand, tetrabenazine is associated with greater cumulative clinical experience than the newer drugs.</p><p class="headingAnchor" id="H2113626139"><span class="h3">Dosing and efficacy</span></p><p class="headingAnchor" id="H4184452511"><span class="h4">Valbenazine</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The recommended starting dose of <a class="drug drug_general" data-topicid="112668" href="/z/d/drug information/112668.html" rel="external">valbenazine</a> is 40 mg daily. The dose can be increased as needed after one or more weeks to a maximum dose of 80 mg daily. The maximum recommended dose is 40 mg/day in patients taking strong CYP2D6 inhibitors (eg, <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a>, <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>)  (<a class="graphic graphic_table graphicRef116164" href="/z/d/graphic/116164.html" rel="external">table 2</a>) or strong CYP3A4 inhibitors  (<a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 3</a>). Specific interactions may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included within UpToDate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – <a class="drug drug_general" data-topicid="112668" href="/z/d/drug information/112668.html" rel="external">Valbenazine</a> was approved for treatment of TD based on the six-week KINECT-2 and KINECT-3 trials [<a href="#rid31">31-34</a>]. The larger KINECT-3 trial enrolled 225 patients with schizophrenia, schizoaffective disorder, or a mood disorder and moderate or severe TD [<a href="#rid31">31</a>]. Patients were randomly assigned to treatment with valbenazine 80 mg once daily, valbenazine 40 mg once daily, or placebo. By intention-to-treat analysis, valbenazine reduced the mean Abnormal Involuntary Movement Scale (AIMS) dyskinesia score, items 1 to 7 of the AIMS  (<a class="graphic graphic_form graphicRef51103" href="/z/d/graphic/51103.html" rel="external">form 1</a>), from baseline to week 6 for the 80 mg/day (-3.2) and 40 mg/day groups (-1.9) compared with placebo (-0.1). Valbenazine treatment at both doses was generally well tolerated. Responses were sustained in a 48-week open-label follow-up study, where there were no differences in efficacy or tolerability for older (&gt;50 years) versus younger patients [<a href="#rid35">35,36</a>].</p><p></p><p class="headingAnchor" id="H2629038359"><span class="h4">Deutetrabenazine</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The starting dose of <a class="drug drug_general" data-topicid="112590" href="/z/d/drug information/112590.html" rel="external">deutetrabenazine</a> is 6 mg twice daily. The dose can be increased weekly in 6 mg/day increments depending on response and tolerability. In a two-year open-label extension study, the mean daily maintenance dose was 38 mg [<a href="#rid37">37</a>]. The maximum recommended dose is 36 mg/day in patients taking strong CYP2D6 inhibitors  (<a class="graphic graphic_table graphicRef116164" href="/z/d/graphic/116164.html" rel="external">table 2</a>) and 48 mg/day in all others. Specific interactions may be determined using the <a class="external" href="/drug-interactions">Lexicomp drug interactions</a> tool (Lexi-Interact online) included in UpToDate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – In the ARM-TD trial, 117 patients with moderate to severe TD were randomly assigned to <a class="drug drug_general" data-topicid="112590" href="/z/d/drug information/112590.html" rel="external">deutetrabenazine</a> or placebo (titrated to a mean total daily dose of approximately 39 mg/day). Over 12 weeks, deutetrabenazine significantly reduced the AIMS score compared with placebo (-3.0 versus -1.6) [<a href="#rid38">38</a>]. However, a clinical global impression of change was not significantly different, despite a trend favoring deutetrabenazine. In the larger 12-week AIM-TD trial, AIMS scores were improved with 36 mg daily of deutetrabenazine (-3.3 versus -1.4) and 24 mg daily (-3.2 versus -1.4) but not with the 12 mg dose [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1">The effect of <a class="drug drug_general" data-topicid="112590" href="/z/d/drug information/112590.html" rel="external">deutetrabenazine</a> appears to be maintained over time, although follow-up data beyond two years are not available. In an open-label extension study that enrolled 343 patients who had completed the AIM-TD or ARM-TD trial, AIMS scores remained stable over a mean treatment duration of approximately one year, and no new safety concerns arose [<a href="#rid37">37</a>]. Limitations of the study included a relatively high rate of attrition, with only 69 percent of patients available for efficacy analysis by week 28.</p><p></p><p class="headingAnchor" id="H3857433641"><span class="h4">Tetrabenazine</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">Tetrabenazine</a> is initiated with 12.5 mg daily for one week and increased by 12.5 mg increments every five to seven days, to a usual effective dose of 75 to 150 mg daily. Because of its relatively short half-life, tetrabenazine is typically dosed three times daily. The maximum recommended single and daily doses are lower (25 and 50 mg, respectively) for patients taking strong CYP2D6 inhibitors  (<a class="graphic graphic_table graphicRef116164" href="/z/d/graphic/116164.html" rel="external">table 2</a>). Specific interactions may be determined using the <a class="external" href="/drug-interactions">Lexicomp drug interactions</a> tool (Lexi-Interact online) included in UpToDate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Efficacy data for <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">tetrabenazine</a> consist of several small, mostly open-label trials in patients with TD [<a href="#rid8">8</a>]. In a double-blind, crossover trial with 24 patients, marked reduction or resolution of dyskinesia occurred in 70 percent of patients treated with tetrabenazine (up to 150 mg daily) [<a href="#rid40">40</a>]. An open-label study in a small group of patients with chronic psychosis found that tetrabenazine was less effective for TD than <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a> [<a href="#rid41">41</a>]. Several open-label studies have demonstrated improvement in TD with tetrabenazine in doses of up to 200 mg daily [<a href="#rid42">42,43</a>].</p><p></p><p class="headingAnchor" id="H2141759174"><span class="h3">Adverse effects and precautions</span><span class="headingEndMark"> — </span>All three VMAT2 inhibitors share common toxicities, most of which relate to their action of depleting synaptic dopamine.</p><p>The most common side effects are somnolence and fatigue. Somnolence usually improves with time and/or slower titration. Less common side effects, reported mainly in studies of <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">tetrabenazine</a>, include akathisia, parkinsonism, depression, tremor, insomnia, confusion, nausea, vomiting, hypotension, and dizziness. With long-term use, the most commonly reported side effects are anxiety, somnolence, and depression [<a href="#rid37">37</a>].</p><p>In addition, all VMAT2 inhibitors carry a boxed warning regarding the risk of depression and suicidality in patients with Huntington disease. Additional warnings include the potential for QT prolongation and neuroleptic malignant syndrome.</p><p class="headingAnchor" id="H2554642233"><span class="h2">Benzodiazepines</span><span class="headingEndMark"> — </span>Prior to the availability of VMAT2 inhibitors, benzodiazepines were commonly used for TD. Although evidence of efficacy is limited, our experience is that a benzodiazepine such as <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a> can be helpful to reduce both dyskinesia and associated anxiety in patients with mild TD, at least in the short term. Patients with more severe TD are less likely to benefit. Tolerance and loss of efficacy limit usefulness as a long-term therapy [<a href="#rid8">8</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">Clonazepam</a> is typically started at 0.5 mg daily and titrated by 0.5 mg increments every five days according to response and as tolerated, up to a maximum of 3 to 4 mg/day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Side effects of benzodiazepines include sedation, confusion, ataxia, and risk of falls, particularly in older adults. Central nervous system depressant effects may be potentiated by barbiturates, hypnotics, anxiolytic, antipsychotic, and antidepressant drugs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Evidence of benefit in patients with TD is limited and inconclusive [<a href="#rid44">44,45</a>]. A systematic review identified four trials in a total of 75 patients with schizophrenia or other chronic psychiatric illness that compared benzodiazepines with placebo, inactive control, or no intervention [<a href="#rid45">45</a>]. In two trials with 32 patients, there was no difference between benzodiazepine treatment and placebo for clinically important improvement, defined as a ≥50 percent improvement in any validated scale for TD (relative risk 1.12, 95% CI 0.60-2.09). A single trial in 21 patients found that more patients taking <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a> had clinically important improvement compared with <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> (60 versus 9 percent).</p><p></p><p class="headingAnchor" id="H1879818005"><span class="h2">Other drug treatments</span><span class="headingEndMark"> — </span>Beyond VMAT2 inhibitors and benzodiazepines, there is insufficient evidence to support routine use of any other drugs for TD, although many have been studied.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amantadine</strong> – <a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">Amantadine</a> may be useful as an adjunct therapy if antipsychotics need to be continued [<a href="#rid8">8</a>]. An 18-week crossover trial that randomly assigned 16 patients to amantadine (300 mg/day) or placebo showed that amantadine could be used without exacerbating psychotic symptoms [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ginkgo biloba extract</strong> – A Chinese randomized controlled trial evaluated the effects of a standardized extract of Ginkgo biloba leaves known as EGb-761 in 157 patients with schizophrenia and TD [<a href="#rid47">47</a>]. After 12 weeks, treatment with EGb-761 significantly decreased the AIMS score, with 51 percent of the treatment group achieving ≥30 percent reduction in the AIMS score versus 5.1 percent of the placebo group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Others</strong> – A number of other agents have been evaluated for TD with mixed or negative results, including <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a>, beta blockers, calcium channel blockers, serotonin antagonists, gamma-aminobutyric acid (GABA) agonists, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a>, <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">buspirone</a>, <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">vitamin B6</a>, and <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> [<a href="#rid8">8,48-55</a>].</p><p></p><p class="headingAnchor" id="H21"><span class="h2">Deep brain stimulation (DBS)</span><span class="headingEndMark"> — </span>Patients with persistent, disabling TD that is unresponsive to pharmacologic treatment may benefit from referral to a multidisciplinary movement disorders clinic for consideration of DBS.</p><p>DBS of the globus pallidus interna (GPi) is well established as a treatment for medically refractory idiopathic primary dystonia and Parkinson disease, with a particular benefit in reduction of levodopa-induced dyskinesia. It follows that pallidal DBS was adopted for other hyperkinetic disorders such as TD. (See  <a class="medical medical_review" href="/z/d/html/4897.html" rel="external">"Device-assisted and lesioning procedures for Parkinson disease"</a> and  <a class="medical medical_review" href="/z/d/html/4887.html" rel="external">"Treatment of dystonia in children and adults", section on 'Surgical therapy'</a>.)</p><p>Limited data in patients with refractory TD suggest that it is reasonable to pursue in select patients [<a href="#rid8">8,11,29</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory TD</strong> – One of the larger prospective studies of DBS for TD included 19 patients with resolved or stabilized psychiatric disease who had severe TD refractory to medical treatment [<a href="#rid56">56</a>]. All were treated with bilateral DBS of the GPi. Six months after surgical lead implantation, blinded evaluations revealed significantly lower Extrapyramidal Symptoms Rating Scale (ESRS) scores with stimulation on compared with stimulation off (mean decrease 49 percent, range 9 to 84 percent). Among 14 patients with long-term (6 to 11 years) follow-up, the improvement in ESRS scores with stimulation "on" was maintained (mean decrease 60 percent, range 22 to 90 percent). Similar short-term and long-term improvement was observed when outcome was assessed with the AIMS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory tardive dystonia</strong> – In case reports and small series, patients with severe forms of TD manifesting primarily as dystonia were successfully treated with DBS of the GPi or subthalamic nucleus [<a href="#rid57">57-62</a>]. These patients displayed various combinations of orofacial, cervical, and truncal dyskinesia and dystonia that improved dramatically within a relatively short period of time after surgery. One unblinded and uncontrolled study of nine patients with refractory tardive dystonia found that benefit of DBS persisted for longer than one year [<a href="#rid62">62</a>].</p><p></p><p class="headingAnchor" id="H231825442"><span class="h1">TARDIVE DYSTONIA</span><span class="headingEndMark"> — </span>Although less common than the classic orofacial dyskinesias of TDs, tardive dystonia is important to recognize because patients may benefit from botulinum toxin injections, which can spare the systemic side effects of oral therapies.</p><p class="headingAnchor" id="H1304345100"><span class="h2">Botulinum toxin injections</span><span class="headingEndMark"> — </span>We suggest botulinum toxin injections for patients with local forms of debilitating tardive dystonia, such as cervical dystonia, retrocollis, oromandibular dystonia, and blepharospasm  (<a class="graphic graphic_algorithm graphicRef131318" href="/z/d/graphic/131318.html" rel="external">algorithm 1</a>) [<a href="#rid5">5</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – The dose of botulinum toxin used depends on site of injection, the serotype, and the formulation. The most common forms of TD treated with botulinum toxin are cervical dystonia, oromandibular dystonia, and blepharospasm (involuntary forced eye closure). Injections are repeated approximately every three months. Adverse effects include excessive weakness of injected or neighboring muscles. Botulinum toxin should be avoided in patients with myasthenia gravis or related neuromuscular conditions.</p><p></p><p class="bulletIndent1">Dosing is individualized according to the form of dystonia, target muscles, and brand and serotype of toxin used. For cervical dystonia, 150 units of <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> (Botox) is a general starting dose that can be increased as needed and tolerated to 300 to 400 units. Blepharospasm can be treated with a lower dose of onabotulinumtoxinA, with typical doses varying between 25 to 75 units in orbicularis oculi and associated facial muscles.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">IncobotulinumtoxinA</a> (Xeomin) and <a class="drug drug_general" data-topicid="9195" href="/z/d/drug information/9195.html" rel="external">abobotulinumtoxinA</a> (Dysport) are alternative formulations of botulinum toxin type A, approved for cervical and other forms of dystonia. It is important to note that dosing of incobotulinumtoxinA is similar to <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> (but not equivalent), while abobotulinumtoxinA requires a larger-unit dose (approximately three to five times higher).</p><p></p><p class="bulletIndent1">For patients who do not respond or become refractory to a type A toxin, <a class="drug drug_general" data-topicid="9155" href="/z/d/drug information/9155.html" rel="external">rimabotulinumtoxinB</a> (Myobloc) can be used. Although it is customary to use rimabotulinumtoxinB as an alternative to type A toxins, it is also possible to use this as the first toxin in a treatment-naive patient. RimabotulinumtoxinB is typically administered in unit doses approximately 40 to 50 times higher than <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> or <a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">incobotulinumtoxinA</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Evidence for the effectiveness of botulinum toxin for TD consists of retrospective case series and case reports [<a href="#rid8">8</a>]. In one multicenter study, botulinum toxin produced marked or moderate improvement in 29 of 34 patients with relatively localized TD manifesting as cervical dystonia or blepharospasm in most cases [<a href="#rid63">63</a>]. In another retrospective study, botulinum toxin treatment was associated with similar improvement in tardive cervical dystonia (n = 7) and idiopathic cervical dystonia (n = 156) [<a href="#rid64">64</a>].</p><p></p><p class="headingAnchor" id="H3571915717"><span class="h2">Nonfocal or refractory dystonia</span><span class="headingEndMark"> — </span>For patients with more widespread tardive dystonia, botulinum toxin injections may not be safe or practical. Vesicular monoamine transporter type 2 (VMAT2) inhibitors are the primary drug therapy for TD. DBS may also be an option in select patients, as reviewed above. (See <a class="local">'Vesicular monoamine transporter type 2 inhibitors'</a> above and <a class="local">'Deep brain stimulation (DBS)'</a> above.)</p><p>Anticholinergic drugs (eg, <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">trihexyphenidyl</a>, <a class="drug drug_general" data-topicid="9106" href="/z/d/drug information/9106.html" rel="external">benztropine</a>) are one additional option for refractory tardive dystonia. Although they are usually ineffective in patients with TD or may even exacerbate choreiform dyskinesias, they are sometimes helpful in ameliorating tardive dystonia. This is consistent with the observation that anticholinergics often exacerbate other hyperkinetic disorders but may be useful in primary dystonia. (See  <a class="medical medical_review" href="/z/d/html/4887.html" rel="external">"Treatment of dystonia in children and adults"</a>.)</p><p>Retrospective studies have shown improvement in tardive dystonia following <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">trihexyphenidyl</a> (10 to 32 mg daily) in three of eight patients [<a href="#rid42">42</a>] and with trihexyphenidyl (6 to 12 mg daily) in 8 of 21 patients [<a href="#rid65">65</a>].</p><p>When used for tardive dystonia, <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">trihexyphenidyl</a> can be initiated at 1 mg twice daily and titrated to a total dose of 4 to 6 mg daily as tolerated.</p><p>Narrow-angle glaucoma, confusion, and dementia are contraindications to the use of <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">trihexyphenidyl</a>. The possibility of exacerbating underlying psychosis is a particular concern in patients with TD. Trihexyphenidyl should be used with caution in people over 60, and in patients with benign prostatic hypertrophy or obstructive gastrointestinal disorders. Other anticholinergic side effects include dry mouth, blurred vision, constipation, urinary hesitancy or retention, tachycardia, pupillary dilatation, and increased intraocular pressure. Patients may develop tolerance to these effects with continued low-dose treatment. Additional side effects of trihexyphenidyl include dizziness, confusion, memory impairment, nausea, vomiting, and anxiety.</p><p class="headingAnchor" id="H1174618635"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Although once considered a persistent or permanent condition, TD is often reversible. In historical studies, remission rates of persistent TD were only 5 to 40 percent, but early identification of TD in younger outpatient populations has been associated with remission in 50 to 90 percent of patients [<a href="#rid66">66</a>]. Remission of TD usually occurs within several months after withdrawal of the offending agent, but may occur as late as one to three years after withdrawal [<a href="#rid67">67</a>].</p><p>Prognosis of TD in patients who require continued antipsychotic drug treatment is not well established, but fortunately, continued antipsychotic drug exposure does not appear to worsen the severity of TD once it becomes established or chronic [<a href="#rid68">68,69</a>]. In most cases, TD either remains unchanged or is suppressed by the hypokinetic effects of an antipsychotic drug.</p><p class="headingAnchor" id="H540315258"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/83900.html" rel="external">"Patient education: Tardive dyskinesia (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Tardive dyskinesia (TD) is a medication-induced hyperkinetic movement disorder that can be disabling and irreversible. All dopamine receptor-blocking agents have the potential to cause TD. The most commonly implicated drugs are antipsychotics and <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a>. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – The only certain way to prevent TD is to avoid chronic administration of dopamine receptor-blocking agents. The use of antipsychotic drugs should be limited to situations where there is no alternative effective therapy. <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">Metoclopramide</a> should not be used continuously for longer than 12 weeks. Particular caution is required in high-risk groups  (<a class="graphic graphic_table graphicRef118233" href="/z/d/graphic/118233.html" rel="external">table 1</a>). (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients receiving long-term antipsychotic drugs or <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> should be regularly screened for the development of TD  (<a class="graphic graphic_form graphicRef51103" href="/z/d/graphic/51103.html" rel="external">form 1</a>). (See <a class="local">'Monitoring during treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If dyskinesia develops during treatment with a dopamine receptor-blocking agent, the offending drug should be discontinued, whenever possible  (<a class="graphic graphic_algorithm graphicRef131318" href="/z/d/graphic/131318.html" rel="external">algorithm 1</a>). Dyskinesias may worsen transiently during withdrawal and may take weeks to months to improve. (See <a class="local">'Discontinue offending agent, if possible'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients who develop TD on a first-generation antipsychotic but still require antipsychotic therapy, we suggest switching to a second-generation antipsychotic drug (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Such a switch seldom worsens TD and may result in a reduction in TD severity, particularly for early and mild symptoms. (See <a class="local">'Patients on a first-generation antipsychotic drug'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who develop TD on a second-generation antipsychotic drug that cannot be discontinued, options include lowering the dose, when possible, switching to <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, and using symptomatic therapy to suppress TD. (See <a class="local">'Patients on a second-generation antipsychotic drug'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptomatic therapy</strong> – Mild TD may not be sufficiently bothersome to require treatment and its associated side effects. For patients with moderate to severe TD, vesicular monoamine transporter type 2 (VMAT2) inhibitors and botulinum toxin injections are the main symptomatic therapies  (<a class="graphic graphic_algorithm graphicRef131318" href="/z/d/graphic/131318.html" rel="external">algorithm 1</a>). (See <a class="local">'Overview of approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with ongoing moderate to severe TD, we suggest treatment with a VMAT2 inhibitor (<a class="drug drug_general" data-topicid="112668" href="/z/d/drug information/112668.html" rel="external">valbenazine</a>, <a class="drug drug_general" data-topicid="112590" href="/z/d/drug information/112590.html" rel="external">deutetrabenazine</a>, or <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">tetrabenazine</a>) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Benzodiazepines are sometimes helpful for mild symptoms but are unlikely to help more severe TD. (See <a class="local">'Vesicular monoamine transporter type 2 inhibitors'</a> above.)</p><p></p><p class="bulletIndent2">The three VMAT2 inhibitors have not been compared directly, and regional availability and cost may vary. When available, we generally prefer the newer agents (<a class="drug drug_general" data-topicid="112668" href="/z/d/drug information/112668.html" rel="external">valbenazine</a> and <a class="drug drug_general" data-topicid="112590" href="/z/d/drug information/112590.html" rel="external">deutetrabenazine</a>), based primarily on longer half-life and convenience.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For the subset of patients with focal tardive dystonia (eg, cervical dystonia), we suggest botulinum toxin injections (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). VMAT2 inhibitors and anticholinergic drugs are an alternative if botulinum toxin is not effective or practical. (See <a class="local">'Botulinum toxin injections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory dyskinesia</strong> – Patients with permanent, disabling TD may be candidates for surgical therapy with deep brain stimulation (DBS) and should be referred to a multidisciplinary movement disorder center for consideration. (See <a class="local">'Deep brain stimulation (DBS)'</a> above.)</p><p></p><p class="headingAnchor" id="H1655025435"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Daniel Tarsy, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Correll CU. Epidemiology and Prevention of Tardive Dyskinesia. J Clin Psychiatry 2017; 78:e1426.</a></li><li><a class="nounderline abstract_t">Correll CU, Kane JM, Citrome LL. Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment. J Clin Psychiatry 2017; 78:1136.</a></li><li><a class="nounderline abstract_t">Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol 2011; 100:601.</a></li><li><a class="nounderline abstract_t">Kass JS, Rose RV. Liability and Failure to Warn a Patient. Continuum (Minneap Minn) 2019; 25:1141.</a></li><li><a class="nounderline abstract_t">Tarsy D. Tardive Dyskinesia. Curr Treat Options Neurol 2000; 2:205.</a></li><li><a class="nounderline abstract_t">Bashir HH, Jankovic J. Treatment of Tardive Dyskinesia. Neurol Clin 2020; 38:379.</a></li><li><a class="nounderline abstract_t">Thomson AM, Wallace J, Kobylecki C. Tardive dyskinesia after drug withdrawal in two older adults: Clinical features, complications and management. Geriatr Gerontol Int 2019; 19:563.</a></li><li><a class="nounderline abstract_t">Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013; 81:463.</a></li><li><a class="nounderline abstract_t">Bergman H, Rathbone J, Agarwal V, Soares-Weiser K. Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev 2018; 2:CD000459.</a></li><li><a class="nounderline abstract_t">Mentzel CL, Bakker PR, van Os J, et al. Effect of Antipsychotic Type and Dose Changes on Tardive Dyskinesia and Parkinsonism Severity in Patients With a Serious Mental Illness: The Curaçao Extrapyramidal Syndromes Study XII. J Clin Psychiatry 2017; 78:e279.</a></li><li><a class="nounderline abstract_t">Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment Recommendations for Tardive Dyskinesia. Can J Psychiatry 2019; 64:388.</a></li><li><a class="nounderline abstract_t">Mentzel TQ, van der Snoek R, Lieverse R, et al. Clozapine Monotherapy as a Treatment for Antipsychotic-Induced Tardive Dyskinesia: A Meta-Analysis. J Clin Psychiatry 2018; 79.</a></li><li><a class="nounderline abstract_t">Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158:503.</a></li><li><a class="nounderline abstract_t">Tamminga CA, Thaker GK, Moran M, et al. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994; 55 Suppl B:102.</a></li><li><a class="nounderline abstract_t">Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997; 12:483.</a></li><li><a class="nounderline abstract_t">Spivak B, Mester R, Abesgaus J, et al. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997; 58:318.</a></li><li><a class="nounderline abstract_t">Hazari N, Kate N, Grover S. Clozapine and tardive movement disorders: a review. Asian J Psychiatr 2013; 6:439.</a></li><li><a class="nounderline abstract_t">Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 1997; 337:809.</a></li><li><a class="nounderline abstract_t">Emsley R, Turner HJ, Schronen J, et al. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 2004; 65:696.</a></li><li><a class="nounderline abstract_t">Sasaki Y, Kusumi I, Koyama T. A case of tardive dystonia successfully managed with quetiapine. J Clin Psychiatry 2004; 65:583.</a></li><li><a class="nounderline abstract_t">Bouckaert F, Herman G, Peuskens J. Rapid remission of severe tardive dyskinesia and tardive dystonia with quetiapine. Int J Geriatr Psychiatry 2005; 20:287.</a></li><li><a class="nounderline abstract_t">Bai YM, Yu SC, Lin CC. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2003; 64:1342.</a></li><li><a class="nounderline abstract_t">Bai YM, Yu SC, Chen JY, et al. Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. Int Clin Psychopharmacol 2005; 20:79.</a></li><li><a class="nounderline abstract_t">Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995; 15:36S.</a></li><li><a class="nounderline abstract_t">Chan HY, Chiang SC, Chang CJ, et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. J Clin Psychiatry 2010; 71:1226.</a></li><li><a class="nounderline abstract_t">Kinon BJ, Jeste DV, Kollack-Walker S, et al. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28:985.</a></li><li><a class="nounderline abstract_t">Brar JS, Parepally H, Chalasani L, et al. The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population. Ann Clin Psychiatry 2008; 20:139.</a></li><li><a class="nounderline abstract_t">Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry 2020; 177:868.</a></li><li><a class="nounderline abstract_t">Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm. J Neurol Sci 2018; 389:67.</a></li><li><a class="nounderline abstract_t">Stacy M, Sajatovic M, Kane JM, et al. Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference. Mov Disord 2019; 34:1203.</a></li><li><a class="nounderline abstract_t">Hauser RA, Factor SA, Marder SR, et al. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am J Psychiatry 2017; 174:476.</a></li><li><a class="nounderline abstract_t">O'Brien CF, Jimenez R, Hauser RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord 2015; 30:1681.</a></li><li><a class="nounderline abstract_t">McIntyre RS, Calabrese JR, Nierenberg AA, et al. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder. J Affect Disord 2019; 246:217.</a></li><li><a class="nounderline abstract_t">Correll CU, Cutler AJ, Kane JM, et al. Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study. J Clin Psychiatry 2018; 80.</a></li><li><a class="nounderline abstract_t">Marder SR, Singer C, Lindenmayer JP, et al. A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia. J Clin Psychopharmacol 2019; 39:620.</a></li><li><a class="nounderline abstract_t">Sajatovic M, Alexopoulos GS, Burke J, et al. The effects of valbenazine on tardive dyskinesia in older and younger patients. Int J Geriatr Psychiatry 2020; 35:69.</a></li><li><a class="nounderline abstract_t">Fernandez HH, Stamler D, Davis MD, et al. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry 2019; 90:1317.</a></li><li><a class="nounderline abstract_t">Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology 2017; 88:2003.</a></li><li><a class="nounderline abstract_t">Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry 2017; 4:595.</a></li><li><a class="nounderline abstract_t">Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry 1972; 27:95.</a></li><li><a class="nounderline abstract_t">Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry 1973; 130:479.</a></li><li><a class="nounderline abstract_t">Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord 1986; 1:193.</a></li><li><a class="nounderline abstract_t">Lang AE, Marsden CD. Alpha methylparatyrosine and tetrabenazine in movement disorders. Clin Neuropharmacol 1982; 5:375.</a></li><li><a class="nounderline abstract_t">Thaker GK, Nguyen JA, Strauss ME, et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry 1990; 147:445.</a></li><li><a class="nounderline abstract_t">Bergman H, Bhoopathi PS, Soares-Weiser K. Benzodiazepines for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev 2018; 1:CD000205.</a></li><li><a class="nounderline abstract_t">Angus S, Sugars J, Boltezar R, et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1997; 17:88.</a></li><li><a class="nounderline abstract_t">Zhang WF, Tan YL, Zhang XY, et al. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011; 72:615.</a></li><li><a class="nounderline abstract_t">Bona JR. Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series. J Clin Psychopharmacol 2006; 26:215.</a></li><li><a class="nounderline abstract_t">Konitsiotis S, Pappa S, Mantas C, Mavreas V. Levetiracetam in tardive dyskinesia: an open label study. Mov Disord 2006; 21:1219.</a></li><li><a class="nounderline abstract_t">Adelufosi AO, Abayomi O, Ojo TM. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2015; :CD010501.</a></li><li><a class="nounderline abstract_t">Essali A, Soares-Weiser K, Bergman H, Adams CE. Calcium channel blockers for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev 2018; 3:CD000206.</a></li><li><a class="nounderline abstract_t">Soares-Weiser K, Rathbone J, Ogawa Y, et al. Miscellaneous treatments for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev 2018; 3:CD000208.</a></li><li><a class="nounderline abstract_t">Alabed S, Latifeh Y, Mohammad HA, Bergman H. Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev 2018; 4:CD000203.</a></li><li><a class="nounderline abstract_t">Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol 2007; 27:159.</a></li><li><a class="nounderline abstract_t">Adler LA, Rotrosen J, Edson R, et al. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry 1999; 56:836.</a></li><li><a class="nounderline abstract_t">Pouclet-Courtemanche H, Rouaud T, Thobois S, et al. Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. Neurology 2016; 86:651.</a></li><li><a class="nounderline abstract_t">Trottenberg T, Paul G, Meissner W, et al. Pallidal and thalamic neurostimulation in severe tardive dystonia. J Neurol Neurosurg Psychiatry 2001; 70:557.</a></li><li><a class="nounderline abstract_t">Eltahawy HA, Feinstein A, Khan F, et al. Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: a case report. Mov Disord 2004; 19:969.</a></li><li><a class="nounderline abstract_t">Franzini A, Marras C, Ferroli P, et al. Long-term high-frequency bilateral pallidal stimulation for neuroleptic-induced tardive dystonia. Report of two cases. J Neurosurg 2005; 102:721.</a></li><li><a class="nounderline abstract_t">Trottenberg T, Volkmann J, Deuschl G, et al. Treatment of severe tardive dystonia with pallidal deep brain stimulation. Neurology 2005; 64:344.</a></li><li><a class="nounderline abstract_t">Tai CH, Tseng SH, Liu HM, Wu RM. Bilateral deep brain stimulation of subthalamic nucleus alleviates tardive dystonia. Neurology 2006; 66:1778.</a></li><li><a class="nounderline abstract_t">Gruber D, Trottenberg T, Kivi A, et al. Long-term effects of pallidal deep brain stimulation in tardive dystonia. Neurology 2009; 73:53.</a></li><li><a class="nounderline abstract_t">Tarsy D, Kaufman D, Sethi KD, et al. An open-label study of botulinum toxin A for treatment of tardive dystonia. Clin Neuropharmacol 1997; 20:90.</a></li><li><a class="nounderline abstract_t">Brashear A, Ambrosius WT, Eckert GJ, Siemers ER. Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov Disord 1998; 13:158.</a></li><li><a class="nounderline abstract_t">Suzuki T, Hori T, Baba A, et al. Effectiveness of anticholinergics and neuroleptic dose reduction on neuroleptic-induced pleurothotonus (the Pisa syndrome). J Clin Psychopharmacol 1999; 19:277.</a></li><li><a class="nounderline abstract_t">Tarsy D. History and definition of tardive dyskinesia. Clin Neuropharmacol 1983; 6:91.</a></li><li><a class="nounderline abstract_t">Tarsy D, Baldessarini RJ. Tardive dyskinesia. Annu Rev Med 1984; 35:605.</a></li><li><a class="nounderline abstract_t">Gardos G, Casey DE, Cole JO, et al. Ten-year outcome of tardive dyskinesia. Am J Psychiatry 1994; 151:836.</a></li><li><a class="nounderline abstract_t">Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology 2001; 56:805.</a></li></ol></div><div id="topicVersionRevision">Topic 4908 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29345874" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Epidemiology and Prevention of Tardive Dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29022654" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21496610" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31356297" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Liability and Failure to Warn a Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11096748" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Tardive Dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32279716" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Treatment of Tardive Dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31157524" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Tardive dyskinesia after drug withdrawal in two older adults: Clinical features, complications and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23897874" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29409162" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28199071" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effect of Antipsychotic Type and Dose Changes on Tardive Dyskinesia and Parkinsonism Severity in Patients With a Serious Mental Illness: The Curaçao Extrapyramidal Syndromes Study XII.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30791698" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Treatment Recommendations for Tardive Dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30257080" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clozapine Monotherapy as a Treatment for Antipsychotic-Induced Tardive Dyskinesia: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1675900" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The effects of clozapine on tardive dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7961550" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clozapine in tardive dyskinesia: observations from human and animal model studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9251065" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The emerging role of clozapine in the treatment of movement disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9269253" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24309853" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clozapine and tardive movement disorders: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9295240" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15163258" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15119928" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A case of tardive dystonia successfully managed with quetiapine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15770692" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Rapid remission of severe tardive dyskinesia and tardive dystonia with quetiapine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14658949" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15729082" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7537286" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20441726" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15380859" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18633740" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32867516" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29454493" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31234240" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28320223" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26346941" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30583148" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30695293" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31688452" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31617235" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The effects of valbenazine on tardive dyskinesia in older and younger patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31296586" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28446646" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28668671" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4555831" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4570750" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2904118" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Natural history and treatment of tardive dystonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6130839" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Alpha methylparatyrosine and tetrabenazine in movement disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1969244" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29352477" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Benzodiazepines for antipsychotic-induced tardive dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10950469" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20868638" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16633158" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16637037" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Levetiracetam in tardive dyskinesia: an open label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25866243" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29578611" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Calcium channel blockers for antipsychotic-induced tardive dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29552749" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Miscellaneous treatments for antipsychotic-induced tardive dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29663328" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17390261" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Tardive dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12892048" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26791148" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11254790" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Pallidal and thalamic neurostimulation in severe tardive dystonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15300668" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15871516" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Long-term high-frequency bilateral pallidal stimulation for neuroleptic-induced tardive dystonia. Report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668437" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Treatment of severe tardive dystonia with pallidal deep brain stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Bilateral deep brain stimulation of subthalamic nucleus alleviates tardive dystonia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19564584" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Long-term effects of pallidal deep brain stimulation in tardive dystonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9037579" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : An open-label study of botulinum toxin A for treatment of tardive dystonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9452343" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10350039" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Effectiveness of anticholinergics and neuroleptic dose reduction on neuroleptic-induced pleurothotonus (the Pisa syndrome)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6133621" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : History and definition of tardive dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6144288" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Tardive dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7910437" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Ten-year outcome of tardive dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11274325" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
